Quarterly Result12 Aug 2025, 04:51 pm
Sanjivani Paranteral Ltd Reports 8.9% YoY Revenue Growth in Q1 FY26, Despite Injectables Segment Surge and Oral Segment Decline
AI Summary
Sanjivani Paranteral Ltd, a Mumbai-based pharmaceutical company, reported a steady performance for the quarter ended 30 June 2025. The company's revenue from operations grew by 8.9% YoY to Rs. 178.9 mn. The injectables segment reported a strong growth of 47.1% YoY, while the oral segment declined by 11.1% YoY. The nutraceuticals segment stood at Rs. 0.8 mn in Q1FY26. Exports, which contributed significantly to the overall revenue, constituted 73.7% of the total revenue. The company remains committed to its long-term strategy, investing in R&D to expand its product portfolio.
Key Highlights
- Revenue from operations grew 8.9% YoY to Rs. 178.9 mn.
- EBITDA margin stood at 15.0% (up 26 bps YoY).
- Profit After Tax (PAT) stood at Rs. 17.3 mn. (up 1.0% YoY).
- Injectables segment revenue grew by 47.1% YoY to Rs. 89.9 mn.
- Oral segment revenue declined by 11.1% YoY to Rs. 88.2 mn.
- Exports constitute 73.7% of total revenue.